Chemokine CXCL14; a double-edged sword in cancer development
- 1 August 2021
- journal article
- review article
- Published by Elsevier in International Immunopharmacology
- Vol. 97, 107681
Abstract
No abstract availableKeywords
This publication has 69 references indexed in Scilit:
- Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancerInternational Journal of Oncology, 2013
- Chemokine CXCL14 is associated with prognosis in patients with colorectal carcinoma after curative resectionJournal of Translational Medicine, 2013
- The Chemokine Superfamily RevisitedImmunity, 2012
- Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosisOncogene, 2010
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- Mitochondrial Dysfunction and Reactive Oxygen Species Imbalance Promote Breast Cancer Cell Motility through a CXCL14-Mediated MechanismCancer Research, 2009
- CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growthProceedings of the National Academy of Sciences, 2009
- Gene Expression Profiling of Papillary Thyroid Carcinoma Identifies Transcripts Correlated with BRAF Mutational Status and Lymph Node MetastasisClinical Cancer Research, 2008
- BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cellsBiochemical and Biophysical Research Communications, 2006
- Cloning of BRAK, a Novel Divergent CXC Chemokine Preferentially Expressed in Normal versus Malignant CellsBiochemical and Biophysical Research Communications, 1999